

FEB 13, 2024

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

Entrustment Agreement with Takeda Pharmaceutical Company Limited.

We are pleased to announce that we have resolved to enter into an entrustment agreement with Takeda Pharmaceutical Company Limited ("Takeda") for antibody generation using the ADLib® system, our antibody generation technology.

1. Outline of the Agreement

We have had entered into a separate outsourcing agreement with Takeda to conduct antibody generation, etc. using the ADLib® System. By entering into the Entrusment Agreement, we will be able to provide research support services rapidly to Takeda, such as antibody production.

2. Outline of Contract Partner

(1) Trade name	Takeda Pharmaceutical Company Limited		
(2) Address	1-1, Doshomachi 4-chome, Chuo-ku, Osaka		
(3) Name and title of representative	President & CEO Christophe Weber		
(4) Nature of business	Research & Development, Manufacturing, and Sales and Marketing of Pharmaceutical Drugs, etc.		
(5) Share capital	¥1,676,345 million (As of March 31, 2023)		
(6) Incorporated	1925		
(7) Number of Shares	1,582,296,025 shares (as of March 31, 2023)		
(8) Relationship between the listed company and the company	Capital relationship	N/A	
	Personnel relationship	N/A	
	Business relationship	The company has business transactions related to antibody generation, etc.	
	Status relationship with Related party	N/A	
(9) Consolidated results of operations and consolidated financial position of the company in the most recent three-year period (IFRS) (Unit: million)			
Fiscal year end	Year ending March 31, 2021	Year ending March 31, 2022	Year ending March 31, 2023
Total capital	5,177,177	5,683,523	6,354,672
Total assets	12,912,293	13,178,018	13,957,750
Revenue	3,197,812	3,569,006	4,027,478

Operating income	509,269	460,844	490,505
Net income	376,171	230,166	317,038
Basic earnings per share (yen)	240.72	147.14	204.29
Dividend per share (yen)	180.00	180.00	180.00

3. Future Outlook

This conclusion expects only minor impact on the financial performance in the fiscal period ending December 31, 2024. Please refer to the "Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2023" dated February 13, 2024 for the forecast of the drug discovery support business for the fiscal year ending December 31, 2024.

<About ADLib® system>

It is a technology to generate antibodies by recombinant activation of antibody genes in chicken DT40 cells and has following characteristics: 1) Rapid production of therapeutic and diagnostic candidate antibodies (as little as 10 days from selection to screening), 2) Capable of generating antibodies based on a unique diversification mechanism and 3) Easy to enhance the binding strength of the obtained antibody to its target (affinity maturation). ADLib® is our registered trademark.

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail:ir@chiome.co.jp